| Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem cell-derived exosomes for COVID-19 treatment |
| Kaavya Jayaramayya1 (Ph.D. course Student), Iyer Mahalaxmi1 (Ph.D. course Student), Mohana Devi Subramaniam2 (Principal Scientist), Neethu Raj3 (Research Scholar), Ahmed Abdal Dayem4 (Research Professor), Kyungmin Lim4 (Ph.D. course Student), Se Jong Kim4 (Ph.D. course Student), Jong Yub An4 (M.Sc. course Student), Yoonjoo Lee4 (M.Sc. course Student), Arthi Kirubhakaran3 (M.Sc. course Student), Ssang-Goo Cho4 (Professor), Balachandar Vellingiri3,* (Assistant Professor) |
1Department of Zoology, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore 641-043, India,
2SN ONGC Department of Genetics and Molecular Biology, Vision Research Foundation, Sankara Nethralaya campus, Chennai – 600 006, India,
3Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore 641-046, India,
4Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul 05029, Korea |
|
Abstract
The world has witnessed unimaginable damages at the hands of the coronavirus disease-19 (COVID-19) pandemic. As the pandemic is growing rapidly, it is important to consider diverse treatment options to effectively treat people world-wide. As the immune system reveals itself at the hub of the infection, it is essential to regulate the dynamic balance in order to prevent the overexaggerated immune responses that subsequently results in multiorgan damage. The value of stem cells as treatment options has gained tremendous momentum in the past decade. The revolutionary measures in science have brought to the world, mesenchymal stem cells (MSCs) and MSC-derived exosomes (MSC-Exo) as therapeutic opportunities in various disease conditions. The MSCs and MSC-Exos have been known to exhibit immunomodulatory functions. These MSCs and MSC-Exos can be used as therapy to strike a balance in the immune cells of patients with COVID-19. In this review, we have discussed the basics of the cytokine storm in COVID-19, MSCs and MSC-derived exosomes and their potential and stem cell-based ongoing clinical trials for COVID-19.
|
| Abstract, Accepted Manuscript(in press) [Submitted on June 5, 2020, Accepted on July 22, 2020] |
|